Global Information
회사소개 | 문의 | 비교리스트

세계의 에스오메프라졸 시장(2020-2026년)

Global Esomeprazole Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949518
페이지 정보 영문
가격
US $ 3,600 ₩ 4,034,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,379,000 Printable PDF (Enterprise License)


세계의 에스오메프라졸 시장(2020-2026년) Global Esomeprazole Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 에스오메프라졸 시장은 2020-2026년간 완만한 성장률을 나타낼 것으로 예상됩니다. 에스오메프라졸은 Nexium 브랜드명으로 미국 FDA로부터 AstraZeneca plc에게 최초로 승인되었습니다. 위식도 역류증(GERD)의 높은 발생률은 세계 시장 성장 주요인 중 하나입니다. 2017년 미국에서는 에스오메프라졸만 약 900만회 처방되었습니다. 하지만, 처방수는 2011년 이후 지속적으로 감소하고 있습니다. 에스오메프라졸 대체약의 존재는 시장 성장 주요 억제요인 중 하나입니다. 에스오메프라졸의 화학 이성체인 오메프라졸은 에스오메프라졸의 가장 일반적인 대체품 하나입니다.

세계의 에스오메프라졸(Esomeprazole) 시장에 대해 조사분석했으며, 시장 개요, 시장 성장 영향요인, 시장 규모와 예측, 부문별 시장 분석, 지역·국가별 시장 분석, 경쟁 구도 등에 대한 정보를 전해드립니다.

목차

제1장 보고서 개요

제2장 시장 개요 및 인사이트

  • 조사 범위
  • 애널리스트 인사이트와 현재 시장 동향
  • 규칙 및 규제

제3장 경쟁 구도

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • AbbVie Inc
    • Sanofi SA
    • Mylan NV
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.

제4장 시장 결정요인

  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제5장 시장 세분화

  • 세계의 에스오메프라졸 시장 : 질환별
    • 미란성 식도염
    • 위식도 역류증
    • 헬리코박터 파일로리 감염증
    • 기타
  • 세계의 에스오메프라졸 시장 : 유형별
    • 브랜드 의약품
    • 제네릭 의약품
  • 세계의 에스오메프라졸 시장 : 투약 유형별
    • 캡슐/정제
    • 주사
    • 기타(서스펜션/현탁액)

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • Alkem Laboratories Ltd.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Chongqing LUMMY Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Inc.
  • Grunenthal GmbH
  • Laboratorios Saval S.A.
  • Lannett Co., Inc.
  • Mylan N.V
  • Novartis AG(Sandoz)
  • Sanofi SA
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
LSH 20.08.10

LIST OF TABLES

  • 1. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 2. GLOBAL EROSIVE ESOPHAGITIS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 4. GLOBAL HELICOBACTER PYLORI INFECTION MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 5. GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 6. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 7. GLOBAL BRANDED ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 8. GLOBAL GENERIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 9. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 10. GLOBAL CAPSULES & TABLETS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 11. GLOBAL INJECTIONS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 12. GLOBAL OTHER DOSAGE TYPE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 17. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 19. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 20. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 21. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 23. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 24. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 25. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 26. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 27. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ESOMEPRAZOLE MARKET SHARE BY DISEASE, 2019 VS 2026 (%)
  • 2. GLOBAL ESOMEPRAZOLE MARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 3. GLOBAL ESOMEPRAZOLE MARKET SHARE BY DOSAGE TYPE, 2019 VS 2026 (%)
  • 4. GLOBAL ESOMEPRAZOLE MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 5. US ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. CANADA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. UK ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. FRANCE ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. GERMANY ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ITALY ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. SPAIN ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. REST OF EUROPE ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. INDIA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. CHINA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. JAPAN ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)

Global Esomeprazole Market Size, Share & Trends Analysis Report, By Disease (Erosive Esophagitis, Gastroesophageal Reflux Disease, Helicobacter Pylori Infection, Other), By Type (Branded and Generic), By Dosage Type (Capsules & Tablets, Injections, and Other) and Forecast, 2020-2026

The global esomeprazole market is anticipated to show a modest growth rate during the forecast period 2020-2026. Esomeprazole was first approved by the US FDA to AstraZeneca plc under the brand name Nexium. High incidences of gastroesophageal reflux disease (GERD) is one of the major factors for the growth of the market all across the globe. In 2017, esomeprazole was prescribed around 9 million times alone in the US. However, prescription numbers are reducing continuously since 2011. The presence of alternative drugs of esomeprazole is one of the major restraining factors for market growth. Omeprazole, a chemical isomer of esomeprazole is one of the most common alternatives of esomeprazole.

The global esomeprazole market is segmented based on disease, type, and dosage type. By disease, the market is further segmented into erosive esophagitis, gastroesophageal reflux disease, helicobacter pylori infection, and others. By type, the market is bifurcated into branded and generic drugs. Significant growth in the generic drug market will be witnessed during the forecast period all across the globe. By dosage type, the market is segmented into capsules & tablets, injections, and others. Capsules & tablets are expected to have a major market share during the forecast period.

By geography, the global esomeprazole market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold a considerable market share. However, significant major market growth will be witnessed in Asia-Pacific due to significant revenue generation of Nexium in Japan and China.

The esomeprazole market is consolidated in nature and a few major market players are operating in the market. Some of the major market players include AbbVie Inc, Sanofi SA, Mylan NV, Novartis AG, Teva Pharmaceutical Industries Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals Inc., and Mylan N.V. The market players are adopting growth strategies including mergers & acquisitions, product approvals, and partnerships & collaborations to gain a competitive edge in the market.

Research Methodology

The market study of the global esomeprazole market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to breakdown the market in various segments; derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to amplify the added validity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

  • Global Esomeprazole Market Research and Analysis, By Disease
  • Global Esomeprazole Market Research and Analysis, By Type
  • Global Esomeprazole Market Research and Analysis, By Dosage Type

The Report Covers:

  • Comprehensive research methodology of the Global Esomeprazole Market.
  • A detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Esomeprazole Market.
  • Insights about market determinants which are stimulating the Global Esomeprazole Market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdowns
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AbbVie Inc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Sanofi SA
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Mylan NV
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Novartis AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Teva Pharmaceutical Industries Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Esomeprazole Market by Disease
    • 5.1.1. Erosive Esophagitis
    • 5.1.2. Gastroesophageal Reflux Disease
    • 5.1.3. Helicobacter Pylori Infection
    • 5.1.4. Other
  • 5.2. Global Esomeprazole Market by Type
    • 5.2.1. Branded
    • 5.2.2. Generic
  • 5.3. Global Esomeprazole Market by Dosage Type
    • 5.3.1. Capsules & Tablets
    • 5.3.2. Injections
    • 5.3.3. Other ( Suspension)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Alkem Laboratories Ltd.
  • 7.2. AstraZeneca plc
  • 7.3. Aurobindo Pharma Ltd.
  • 7.4. Cadila Healthcare Ltd.
  • 7.5. Chongqing LUMMY Pharmaceutical Co., Ltd.
  • 7.6. Dr. Reddy's Laboratories Ltd.
  • 7.7. Glenmark Pharmaceuticals Inc.
  • 7.8. Grunenthal GmbH
  • 7.9. Laboratorios Saval S.A.
  • 7.10. Lannett Co., Inc.
  • 7.11. Mylan N.V
  • 7.12. Novartis AG (Sandoz)
  • 7.13. Sanofi SA
  • 7.14. Stada Arzneimittel AG
  • 7.15. Sun Pharmaceutical Industries Ltd.
  • 7.16. Teva Pharmaceutical Industries Ltd.
Back to Top
전화 문의
F A Q